Related references
Note: Only part of the references are listed.The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL
Karin S. Coyne et al.
NEUROUROLOGY AND URODYNAMICS (2013)
Effect of Bothersome Overactive Bladder Symptoms on Health-related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results From EpiLUTS
Ian Milsom et al.
UROLOGY (2012)
Analysis of the Risk Factors for Overactive Bladder on the Basis of a Survey in the Community
Jung Ki Jo et al.
KOREAN JOURNAL OF UROLOGY (2012)
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial
Steven A. Kaplan et al.
BJU INTERNATIONAL (2011)
Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder
Shizuo Yamada et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats
Takanobu Yamazaki et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)
Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study
Young-Suk Lee et al.
WORLD JOURNAL OF UROLOGY (2011)
Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
Masayoshi Zaitsu et al.
ADVANCES IN UROLOGY (2011)
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial
Sender Herschorn et al.
BJU INTERNATIONAL (2010)
Efficacy and Tolerability of Fesoterodine in Older and Younger Subjects With Overactive Bladder
Stephen R. Kraus et al.
UROLOGY (2010)
Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo
Philip E. V. Van Kerrebroeck et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2009)
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder
Yukio Homma et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis
Christopher R. Chapple et al.
EUROPEAN UROLOGY (2008)
A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder
Yukio Homma et al.
INTERNATIONAL JOURNAL OF UROLOGY (2008)
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin
CJ Kelleher et al.
BJU INTERNATIONAL (2005)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
The standardisation of terminology of lower urinary tract function: Report from the of the International Standardisation Sub-Committee Continence Society
P Abrams et al.
NEUROUROLOGY AND URODYNAMICS (2002)
Share Paper
